Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Protriptyline hydrochloride
Drug ID BADD_D01873
Description Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, alpha1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
Indications and Usage For the treatment of depression.
Marketing Status Prescription; Discontinued
ATC Code N06AA11
DrugBank ID DB00344
KEGG ID D00484
MeSH ID D011530
PubChem ID 6603149
TTD Drug ID D00MYQ
NDC Product Code 63629-8346; 42794-004; 42806-097; 42794-007; 46438-0066; 0054-0211; 50383-960; 64980-158; 50383-959; 42806-096; 64980-159; 46438-0056; 17337-0539; 0054-0210
Synonyms Protriptyline | Vivactil | Protriptyline Hydrochloride | Hydrochloride, Protriptyline
Chemical Information
Molecular Formula C19H22ClN
CAS Registry Number 1225-55-4
SMILES CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Parotid gland enlargement07.06.03.001--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Purpura24.07.06.005; 01.01.04.003; 23.06.01.004--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Restlessness17.02.05.021; 19.11.02.002--
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Testicular swelling21.13.01.003--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue discolouration07.14.02.006--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urinary tract malformation20.08.03.002; 03.06.02.003--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychotic disorder19.03.01.002--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages